An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

Review expert insights on the latest developments in managing myelodysplastic syndromes with a focused commentary downloadable slides podcast and on-demand webcast from a live CCO symposium at ASH 2022.

Share

Program Content

No activities added yet

Activities

Managing Lower-risk MDS
Strategies for Managing Very Low-Risk, Low-Risk and Intermediate-Risk MDS
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

TX for Higher Risk MDS
Emerging Therapies in the Treatment of Patients With Higher Risk MDS in Frontline and Post-HMA Failure Settings
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

MDS Classification and Risk
Myelodysplastic Syndromes: Diagnosis, Classification, and Risk Stratification
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

EP: MDS Personalized Management
Express Points An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2022

Expires: December 20, 2023

Activities

MDS Tx Challenges
Challenges in Personalizing the Management of Myelodysplastic Syndromes: Case Studies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2022

Expires: November 15, 2023

Provided by

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Learning Objectives

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy

  • Manage treatment-related symptoms associated with the treatment of RET-altered or
    NTRK fusion–positive cancer

  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials